Armored vehicles can be defined as the combat or non-combat vehicles which are fitted with additional armor plating in order to provide protection from projectiles, bullets, grenades, shell fragments and mines among others. These vehicles are capable of facing fierce situations with very little or no threats to the occupants of the vehicles. Such vehicles are either equipped with guns with heavy caliber or are used for transportation of military personnel. Consequently, armored vehicles hold equal importance in combat as well as transportation applications and hence, the demand for such vehicles is experiencing a consistent surge.
The generic oncology drugs market is set to growth at a compounded annual growth rate (CAGR) of 6.1% during the forecast period from 2025 to 2033. According to the statistics provided by World Health Organization (WHO) in 2025, 9.6 million people worldwide have been estimated to be dead due to cancer. It is considered as the second leading cause of death, researchers are of the opinion that approximately 30% cancer deaths can be prevented by avoiding risk factors such as alcohol consumption, tobacco smoking, early diagnosis etc.
The global ligament stabilizers market is Increasing incidences of sports injuries, trauma cases and other ligament injuries due to accidents at work or home will drive the market growth globally. New product development for knee and ankle joints along with expansion of branded products in the emerging nations will drive the ligament stabilizers market.
The global Zygomatic and pterygoid implants market was valued at more than US$ 302.4 million in 2021 and is expected to reach over US$ 576.44 million by 2033, expanding at a CAGR of 6.0% from 2025 to 2033.
Cutaneous mastocytosis treatment market accounted for a market value of US$ 230.27 Mn in 2021 and projected to grow at a CAGR of 5.6% during the forecast period from 2025 to 2033. Cutaneous mastocytosis is a rare disease in which uncontrolled production of mast cells leads to skin complications such as lesions, blisters, and rashes with aggravated itching.
Dental biomaterials market accounted for grow at a CAGR of 7.3% during the forecast period from 2025 to 2033. According to World Health Organization (WHO), dental caries is one of the major public health issues in most of the developed countries, as the disease affects 60-90% of children and the majority of adults. Currently, the distribution and severity of dental caries may differ in various parts of the world and sometimes within the region or country.
The Intravitreal injectables market will be showcasing stable growth at a compound annual growth rate (CAGR) of 4.8% during the forecast period from 2025 to 2033. According to the statistics provided by World Health Organization (WHO) approximately 1.3 billion people throughout the globe are suffering with some form of blindness caused majorly due to macular degeneration, diabetic retinopathy, ocular vein occlusions, endophthalmitis and retinitis. Intravitreal injections are being preferred over other treatment options for treating disease associated visual impairment.
Bronchitis treatment market accounted for a market value of US$ 3,509.7 Mn in 2021 and is projected to grow at a CAGR of 4.9% during the forecast period from 2025 to 2033. Bronchitis treatment market is growing gradually throughout the forecast period due to strong product pipeline equipped with target-specific drugs, and rising prevalence & awareness related to the treatment & diagnosis of bronchitis. The major cause of bronchitis is frequent cigarette smoking coupled with exposure to air pollutants.
The preterm birth and PROM testing market is set to growth at a compounded annual growth rate (CAGR) of 2.1% during the forecast period from 2025 to 2033. As per the research findings of World Health Organization (WHO), annually 15 million babies are born before the completion of 37 weeks of normal pregnancy and as a result approximately 1 million children die every year due to complications associated with preterm births.
Growing regulatory pressure and challenge of litigations over adverse or side effects, rapidly changing demographic patterns, drying product pipelines and consistent growth in competition from generic manufacturers are some of the prime challenges faced in the life sciences business. Further growth in cost of drug development, approvals and growing responsibilities and obligations on the regulatory front have driven organizations to adopt outsourcing services for regulatory operations.